PT4037685T - Quinolina que modula serca e sua utilização no tratamento de doenças - Google Patents

Quinolina que modula serca e sua utilização no tratamento de doenças

Info

Publication number
PT4037685T
PT4037685T PT218458321T PT21845832T PT4037685T PT 4037685 T PT4037685 T PT 4037685T PT 218458321 T PT218458321 T PT 218458321T PT 21845832 T PT21845832 T PT 21845832T PT 4037685 T PT4037685 T PT 4037685T
Authority
PT
Portugal
Prior art keywords
serca
quinolines
modulate
treating disease
disease
Prior art date
Application number
PT218458321T
Other languages
English (en)
Portuguese (pt)
Original Assignee
Neurodon Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US16/932,832 external-priority patent/US20200347038A1/en
Application filed by Neurodon Corp filed Critical Neurodon Corp
Publication of PT4037685T publication Critical patent/PT4037685T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/40—Nitrogen atoms attached in position 8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PT218458321T 2020-07-20 2021-07-19 Quinolina que modula serca e sua utilização no tratamento de doenças PT4037685T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US16/932,832 US20200347038A1 (en) 2014-08-29 2020-07-20 Quinolines that modulate serca and their use for treating disease

Publications (1)

Publication Number Publication Date
PT4037685T true PT4037685T (pt) 2023-12-28

Family

ID=79729478

Family Applications (1)

Application Number Title Priority Date Filing Date
PT218458321T PT4037685T (pt) 2020-07-20 2021-07-19 Quinolina que modula serca e sua utilização no tratamento de doenças

Country Status (11)

Country Link
EP (1) EP4037685B9 (enExample)
JP (1) JP7705445B2 (enExample)
CN (1) CN116744928A (enExample)
CA (1) CA3186668A1 (enExample)
DK (1) DK4037685T3 (enExample)
ES (1) ES2968041T3 (enExample)
FI (1) FI4037685T3 (enExample)
HU (1) HUE064550T2 (enExample)
PL (1) PL4037685T3 (enExample)
PT (1) PT4037685T (enExample)
WO (1) WO2022020261A1 (enExample)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101784533B (zh) * 2007-08-22 2013-08-21 艾博特股份有限两合公司 4-苄基氨基喹啉、含有它们的药物组合物和它们在治疗中的用途
CN104302640A (zh) * 2012-03-16 2015-01-21 埃克希金医药品有限公司 3,5-二氨基吡唑激酶抑制剂
US10772881B2 (en) * 2017-02-27 2020-09-15 Russell Dahl Quinolines that modulate SERCA and their use for treating disease
US20170281611A1 (en) * 2014-08-29 2017-10-05 Eiger Biopharmaceuticals, Inc. Quinolines and their use for treating endoplasmic reticulum stress-caused diseases
US20200347038A1 (en) * 2014-08-29 2020-11-05 Russell Dahl Quinolines that modulate serca and their use for treating disease
CN106966973A (zh) * 2017-05-18 2017-07-21 湖北工业大学 N‑苯基‑n‑(2‑甲基‑8‑喹啉基)苯甲酰胺的制备方法

Also Published As

Publication number Publication date
WO2022020261A1 (en) 2022-01-27
JP7705445B2 (ja) 2025-07-09
FI4037685T3 (fi) 2023-11-27
EP4037685A4 (en) 2022-11-30
DK4037685T3 (en) 2024-01-02
EP4037685B1 (en) 2023-09-20
WO2022020261A9 (en) 2022-09-09
CA3186668A1 (en) 2022-01-27
ES2968041T3 (es) 2024-05-06
CN116744928A (zh) 2023-09-12
HUE064550T2 (hu) 2024-03-28
EP4037685B9 (en) 2024-03-06
PL4037685T3 (pl) 2024-04-02
JP2023534992A (ja) 2023-08-15
EP4037685A1 (en) 2022-08-10

Similar Documents

Publication Publication Date Title
EP3968916A4 (en) GLAND TREATMENT DEVICES AND METHODS FOR TREATMENT OF DRY EYES
IL285649A (en) Azepino-indoles and other heterocyclics for the treatment of brain disorders
IL268327A (en) A pharmaceutical preparation for use in the treatment and prevention of c5-related diseases and methods for the treatment and prevention of c5-related diseases
SG11202013239RA (en) Composition and method for treating pain
ZA201905222B (en) Combination treating prostate cancer, pharmaceutical composition and treatment method
SMT202600182T1 (it) Materiali e metodi per il trattamento dell'atassia di friedreich
IL309296A (en) Methods and compositions for the treatment of angiotensinogen-related disorder (AGT-)
IL280475B2 (en) Pharmaceutical preparation for use in the treatment or prevention of a C5-related disease and a method for treating or preventing a C5-related disease
IL304273A (en) Compositions and methods for treating Fabry disease
HUE073261T2 (hu) Készítmények fehérje-aggregációs betegségek kezelésére és/vagy megelõzésére
GB202010844D0 (en) Combar for skin and hair treatment
GB202314118D0 (en) Methods of classifying and treating patients
PL3452475T3 (pl) Tetrahydropyrimidodiazepina i związki tetrahydropyridodiazepiny w leczeniu bólu i chorób związanych z bólem
EP4445914A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF TUMORS AND USE
IL304726A (en) Methods and substances that stimulate the mitochondrial cycle for the treatment of diseases
EP4334718A4 (en) CANCER EVALUATION AND TREATMENT
IL288178A (en) Combined gmci and ddri treatment for cancer
DK4037685T3 (en) Quinoline that modulate serca and its use for treating disease
ZA202105583B (en) Methods of diagnosing and treating cervical cancer
GB202101728D0 (en) Compounds and their use treating cancer
IL291609A (en) Methods for treating acute wounds and improving outcomes
EP4085908A4 (en) PHARMACEUTICAL COMBINATION FOR TREATING TUMORS AND ITS APPLICATION
KR102349013B9 (ko) 멜라토닌을 유효성분으로 포함하는 암의 예방 또는 치료용 약학적 조성물
IL276150A (en) Methods and compositions for treating and preventing skin barrier disruptions
ZA202107319B (en) Method for preventing and treating scab disease